In breast cancer, studies have suggested that increased PIEZO1 expression leads to worse survival outcomes in certain subtypes, including lymph-node-positive, luminal A, and estrogen-receptor-positive patients, but have opposite results in other breast cancer subtypes, such as basal-like breast cancer [35]. Here, PIEZO1 is linked to breast carcinoma.